Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Bicalutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Bicalutamide SCHEMBL5365801 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1561110 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL29353850 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL3611 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1933417 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL3612 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL29354880 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL28262190 | 0.98 | AR (0.96) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL679554 | 0.97 | AR (0.94) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL15325704 | 0.93 | AR (0.87) | ARCYP2C19ABCB11ALBPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576063-B2 | Implantable drug delivery devices for localized drug delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240100010-A9 | Implantable Drug Delivery Devices For Localized Drug Delivery | Alessa Therapeutics, Inc. | 2024-03-28 | — | — | US | disclosed |
| US-20230137168-A1 | Implantable Drug Delivery Devices For Localized Drug Delivery | UNIV CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| CN-115515657-A | Implantable drug delivery device for local drug delivery | 加利福尼亚大学董事会 | 2022-12-23 | — | — | CN | disclosed |
| EP-4100075-A1 | IMPLANTABLE DRUG DELIVERY DEVICES FOR LOCALIZED DRUG DELIVERY | The Regents of University of California (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11344526-B2 | Implantable drug delivery devices for localized drug delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-31 | — | — | US | disclosed |
| US-11338119-B2 | Implantable drug delivery devices for localized drug delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-24 | — | — | US | disclosed |
| CN-105828811-B | Bicalutamide analogs or (S) -bicalutamide as exocytosis activating compounds for use in the treatment of lysosomal storage disorders or glycogen storage diseases | BCN肽类股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576063-B2 | Implantable drug delivery devices for localized drug delivery | AR, MEF2D, SHBG | AR 1/4885CYP2C19 479/4885ABCB11 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.